ATE202383T1 - Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten - Google Patents

Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten

Info

Publication number: ATE202383T1
Authority: AT; Austria
Prior art keywords: hepatitis; virus; methods; compositions; treatment
Prior art date: 1992-09-10

Application number

AT93919644T

Other languages

English (en)

Inventor

Kevin P Anderson

Ronnie C Hanecak

Kazuya Hoshiko

Chikateru Nozaki

Tsukasa Nishihara

Hiroshi Nakatake

Fukusaburo Hamada

Tatsuo Eto

Shinichi Furukawa

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-10

Filing date

1993-09-10

Publication date

2001-07-15

1993-04-14 Priority claimed from JP5087195A external-priority patent/JPH06296492A/ja

1993-09-10 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2001-07-15 Application granted granted Critical

2001-07-15 Publication of ATE202383T1 publication Critical patent/ATE202383T1/de

Links

201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
208000006454 hepatitis Diseases 0.000 title 1
231100000283 hepatitis Toxicity 0.000 title 1
239000000203 mixture Substances 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000000074 antisense oligonucleotide Substances 0.000 abstract 1
238000012230 antisense oligonucleotides Methods 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

AT93919644T 1992-09-10 1993-09-10 Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten ATE202383T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94528992A	1992-09-10	1992-09-10
JP5087195A JPH06296492A (ja)	1993-04-14	1993-04-14	抗ｃ型肝炎ウイルスオリゴヌクレオチド
PCT/JP1993/001293 WO1994005813A1 (en)	1992-09-10	1993-09-10	Compositions and methods for treatment of hepatitis c virus-associated diseases

Publications (1)

Publication Number	Publication Date
ATE202383T1 true ATE202383T1 (de)	2001-07-15

Family

ID=26428490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93919644T ATE202383T1 (de)	1992-09-10	1993-09-10	Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten

Country Status (10)

Country	Link
US (2)	US6284458B1 (de)
EP (1)	EP0662157B1 (de)
JP (1)	JPH08506479A (de)
AT (1)	ATE202383T1 (de)
AU (1)	AU680435B2 (de)
CA (1)	CA2143678A1 (de)
DE (1)	DE69330372T2 (de)
DK (1)	DK0662157T3 (de)
NZ (2)	NZ286209A (de)
WO (1)	WO1994005813A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6174868B1 (en) *	1992-09-10	2001-01-16	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of hepatitis C virus-associated diseases
DE69333914T2 (de) *	1992-09-28	2006-08-10	Chiron Corp., Emeryville	Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
US6824976B1 (en)	1993-04-02	2004-11-30	Rigel Pharmaceuticals, Inc.	Method for selective inactivation of viral replication
JPH10503364A (ja) *	1994-05-10	1998-03-31	ザジェネラルホスピタルコーポレーション	Ｃ型肝炎ウイルスのアンチセンス阻害
AU698739B2 (en) *	1995-06-06	1998-11-05	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
ZA964446B (en) *	1995-06-06	1996-12-06	Hoffmann La Roche	Oligonucleotides specific for hepatitis c virus
US6090557A (en) *	1997-04-18	2000-07-18	Roche Molecular Systems, Inc.	Neisseria gonorrhoeae-specific oligonucleotides
EP1002878A3 (de) *	1998-11-19	2003-11-12	Tosoh Corporation	Hepatitis C Viren RNS-bindendes oligo DNS und Verfahren für dessen Herstellung
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
PL359169A1 (en)	2000-05-26	2004-08-23	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses
AU2002356187A1 (en) *	2001-08-22	2003-03-10	Isis Pharmaceuticals, Inc.	Molecular interaction sites of hepatitis c virus rna and methods of modulating the same
JPWO2003025173A1 (ja) *	2001-09-17	2004-12-24	武今西	Ｃ型肝炎ウイルスに対する新規なアンチセンスオリゴヌクレオチド誘導体
AU2003298658A1 (en)	2002-11-15	2004-06-15	Idenix (Cayman) Limited	2'-branched nucleosides and flaviviridae mutation
FR2848572B1 (fr) *	2002-12-12	2005-12-09	Univ Joseph Fourier	Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
US7833987B2 (en) *	2004-03-12	2010-11-16	Indian Institute Of Science	Small synthetic RNA, a method of preparing the same and uses thereof
CA2824308A1 (en) *	2004-09-24	2006-04-06	Alnylam Pharmaceuticals, Inc.	Targeting opposite strand replication intermediates of single-stranded viruses by rnai
FR2884522A1 (fr) *	2005-04-19	2006-10-20	Larissa Balakireva	Methode d'inhibition de la traduction et/ou la replication d'une sequence d'arn par multimerisation d'une de ses regions d'arn non codant replie
CA3042781C (en)	2006-04-03	2021-10-19	Roche Innovation Center Copenhagen A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100811A1 (ru) *	2006-04-03	2012-06-29	Сантарис Фарма А/С	Фармацевтическая композиция
EP2076597A2 (de) *	2006-10-09	2009-07-08	Santaris Pharma A/S	Rna-antagonistenverbindungen zur modulation von pcsk9
US8481506B2 (en) *	2006-12-05	2013-07-09	Rosetta Genomics, Ltd.	Nucleic acids involved in viral infection
US7951789B2 (en)	2006-12-28	2011-05-31	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
US8580756B2 (en)	2007-03-22	2013-11-12	Santaris Pharma A/S	Short oligomer antagonist compounds for the modulation of target mRNA
US8470791B2 (en)	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
CA2690643A1 (en) *	2007-06-14	2008-12-18	Mirx Therapeutics Aps	Oligonucleotides for modulation of target rna activity
US20110054011A1 (en) *	2007-08-30	2011-03-03	Mccullagh Keith	RNA Antagonist Compounds for the Modulation of FABP4/AP2
DK2205737T3 (da)	2007-10-04	2013-05-21	Santaris Pharma As	Mikromirer
EP2268811A1 (de) *	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8492357B2 (en)	2008-08-01	2013-07-23	Santaris Pharma A/S	Micro-RNA mediated modulation of colony stimulating factors
US9034837B2 (en)	2009-04-24	2015-05-19	Roche Innovation Center Copenhagen A/S	Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
WO2012007477A1 (en) *	2010-07-12	2012-01-19	Santaris Pharma A/S	Anti hcv oligomers
EP3702460A1 (de)	2010-11-12	2020-09-02	The General Hospital Corporation	Polycombassoziierte nichtcodierende rnas
US9243025B2 (en)	2011-03-31	2016-01-26	Idenix Pharmaceuticals, Llc	Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en)	2011-09-12	2016-08-02	Idenix Pharmaceuticals Llc	Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es)	2011-10-14	2014-09-10	Idenix Pharmaceuticals Inc	Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
CN104583402A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节mecp2表达的组合物和方法
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
WO2013177195A1 (en)	2012-05-22	2013-11-28	Idenix Pharmaceuticals, Inc.	3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (de)	2012-05-22	2017-04-12	Idenix Pharmaceuticals LLC	3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
MD20140134A2 (ro)	2012-05-22	2015-04-30	Idenix Pharmaceuticals, Inc.	Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PT2861611T (pt)	2012-05-25	2016-10-11	Janssen Sciences Ireland Uc	Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en)	2012-09-27	2014-04-03	Idenix Pharmaceuticals, Inc.	Esters and malonates of sate prodrugs
ES2674980T3 (es)	2012-10-08	2018-07-05	Idenix Pharmaceuticals Llc	Análogos de 2'-cloro nucleósidos para infección por VHC
ES2659747T3 (es) *	2012-10-18	2018-03-19	F. Hoffmann-La Roche Ag	Ensayo de doble sonda para la detección de poblaciones heterogéneas de amplicón
WO2014066239A1 (en)	2012-10-22	2014-05-01	Idenix Pharmaceuticals, Inc.	2',4'-bridged nucleosides for hcv infection
US10260089B2 (en)	2012-10-29	2019-04-16	The Research Foundation Of The State University Of New York	Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9211300B2 (en)	2012-12-19	2015-12-15	Idenix Pharmaceuticals Llc	4′-fluoro nucleosides for the treatment of HCV
US11274998B2 (en)	2012-12-26	2022-03-15	Ventana Medical Systems, Inc.	Specimen processing systems and methods for holding slides
WO2014137930A1 (en)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (de)	2013-03-13	2025-01-01	Idenix Pharmaceuticals LLC	Aminosäure-phosphoramidat-pronukleotide von 2'-cyano-, azido- und aminonukleosiden zur behandlung von hcv
EP2981542B1 (de)	2013-04-01	2021-09-15	Idenix Pharmaceuticals LLC	2',4'-fluor-nukleoside zur behandlung von hcv
AU2014250762A1 (en)	2013-04-12	2015-10-29	Achillion Pharmaceuticals, Inc.	Highly active nucleoside derivative for the treatment of HCV
EP3004130B1 (de)	2013-06-05	2019-08-07	Idenix Pharmaceuticals LLC.	1',4'-thionukleoside zur behandlung von hcv
MX367083B (es)	2013-06-27	2019-08-05	Roche Innovation Ct Copenhagen As	Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
US20150037282A1 (en)	2013-08-01	2015-02-05	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (de)	2014-04-16	2023-05-10	Idenix Pharmaceuticals LLC	3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
WO2016070060A1 (en)	2014-10-30	2016-05-06	The General Hospital Corporation	Methods for modulating atrx-dependent gene repression
WO2016130943A1 (en)	2015-02-13	2016-08-18	Rana Therapeutics, Inc.	Hybrid oligonucleotides and uses thereof
US10900036B2 (en)	2015-03-17	2021-01-26	The General Hospital Corporation	RNA interactome of polycomb repressive complex 1 (PRC1)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5034506A (en) *	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en) *	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) *	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1989004669A1 (en)	1987-11-18	1989-06-01	Chiron Corporation	Nanbv diagnostics and vaccines
US5714596A (en)	1987-11-18	1998-02-03	Chiron Corporation	NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5004810A (en) *	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
HUT54896A (en) *	1989-03-17	1991-04-29	Chiron Corp	Process for producing aquous diagnosticum and vaccine of nanbv
US5166195A (en) *	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
DE69126617T2 (de) *	1990-08-10	1997-10-02	Chiron Corp	Nanbv diagnostik: für die untersuchung auf hepatitis c verwendbare polynukleotide
AU1459792A (en) *	1991-01-14	1992-08-27	James N. Gamble Institute Of Medical Research	Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
RU2155228C2 (ru) *	1991-05-08	2000-08-27	Чирон Корпорейшн	Hcv геномные последовательности для диагностических и терапевтических целей
CA2070952A1 (en) *	1991-06-11	1992-12-12	Makoto Seki	Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US5610054A (en) *	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
US6057093A (en) *	1992-09-28	2000-05-02	Chiron Corporation	Methods and compositions for controlling translation of HCV proteins
JP3028171B2 (ja) *	1993-08-31	2000-04-04	日本ピラー工業株式会社	複合ガスケット

1993
- 1993-09-10 AT AT93919644T patent/ATE202383T1/de not_active IP Right Cessation
- 1993-09-10 CA CA002143678A patent/CA2143678A1/en not_active Abandoned
- 1993-09-10 DK DK93919644T patent/DK0662157T3/da active
- 1993-09-10 US US08/397,220 patent/US6284458B1/en not_active Expired - Fee Related
- 1993-09-10 NZ NZ286209A patent/NZ286209A/xx unknown
- 1993-09-10 EP EP93919644A patent/EP0662157B1/de not_active Expired - Lifetime
- 1993-09-10 NZ NZ255578A patent/NZ255578A/en unknown
- 1993-09-10 AU AU49837/93A patent/AU680435B2/en not_active Expired
- 1993-09-10 DE DE69330372T patent/DE69330372T2/de not_active Expired - Lifetime
- 1993-09-10 JP JP6507055A patent/JPH08506479A/ja active Pending
- 1993-09-10 WO PCT/JP1993/001293 patent/WO1994005813A1/en not_active Ceased
2003
- 2003-06-09 US US10/457,304 patent/US20040033978A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ286209A (en)	2000-09-29
DE69330372D1 (de)	2001-07-26
JPH08506479A (ja)	1996-07-16
US6284458B1 (en)	2001-09-04
EP0662157A1 (de)	1995-07-12
US20040033978A1 (en)	2004-02-19
NZ255578A (en)	1996-11-26
CA2143678A1 (en)	1994-03-17
AU4983793A (en)	1994-03-29
EP0662157B1 (de)	2001-06-20
WO1994005813A1 (en)	1994-03-17
AU680435B2 (en)	1997-07-31
DE69330372T2 (de)	2002-03-14
DK0662157T3 (da)	2001-08-27

Legal Events

Date	Code	Title	Description
2006-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69330372D1 (de)	2001-07-26	ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
DE69829115D1 (de)	2005-03-31	Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
UA41879C2 (uk)	2001-10-15	Засіб для лікування мотонейронових захворювань
ATE179330T1 (de)	1999-05-15	Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
EA200500487A1 (ru)	2005-10-27	Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
KR960704033A (ko)	1996-08-31	인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
WO1992019743A3 (en)	1993-11-25	Hcv genomic sequences for diagnostics and therapeutics
NO951307L (no)	1995-06-01	Terapeutiske anti-HIV oligonukleotider
MY128441A (en)	2007-02-28	Bipiperidine derivatives as modulators of ccr3 activity and as h1 antogonists
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
NO954217L (no)	1995-12-18	Guanosinrike antivirus-oligonukleotider
DE69613348D1 (de)	2001-07-19	Hemmung der neovaskulasierung durch vegf-spezifische oligonukleotide
ATE465168T1 (de)	2010-05-15	Xylo-lna analoge
HRP20030139B8 (hr)	2015-11-06	Peptidomimetiäśki inhibitori proteaza
PL316197A1 (en)	1996-12-23	Benzothiophene, benzofuran and indole thiazepinones, oxazepinones and diazepinones as agents preventing adhesion of cells and inhibiting activity of hiv virus
DE69626393D1 (de)	2003-04-03	Spezifische oligonukleotide für hepatitis b virus
EP0745090A1 (de)	1996-12-04	Oligonukleotide mit antirespiratorischer synzytialvirus-wirkung
DE60002126D1 (de)	2003-05-22	Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
FR2678284B1 (fr)	1993-10-08	Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes.
MXPA02011969A (es)	2004-09-06	Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
DE69906284T2 (de)	2004-01-29	Diagnostisches verfahren basierend auf der quantifizierung extramitochondrialer dna
DE3580639D1 (de)	1991-01-03	Zubereitungen und verfahren zum schutz von t-lymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
MD940152A (ro)	1995-12-31	Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
DE3873470D1 (de)	1992-09-10	Behandlung von viruskrankheiten.
DE3767069D1 (de)	1991-02-07	Antivirales mittel zur hemmung des wachstums vom aids-syndrom-virus.